• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Vaginal Progesterone Prevent Recurrent Preterm Birth When Cervical Length is >25 mm?

FavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Data is limited regarding the benefit of vaginal progesterone for women with a history of spontaneous preterm birth and a cervix >25 mm
  • Conde-Agudelo et al. (AJOG, 2022) assessed the efficacy of vaginal progesterone in preventing preterm birth in this subset of patients

METHODS:

  • Post-hoc subgroup analysis of previously published meta-analysis
  • Inclusion criteria for original meta-analysis
    • RCTs
    • Studies that compared vaginal progesterone vs placebo or no treatment for recurrent preterm birth prevention
  • Subgroup analysis exposure
    • Short cervix ≤25 mm
    • Cervical length >25 mm
  • Study design
    • Pooled relative risk was calculated by using a random-effects model
    • GRADE criteria were used to assess the quality of evidence
  • Primary outcome
    • Preterm birth <37 and <34 weeks
  • Secondary outcomes
    • Maternal and neonatal outcomes

RESULTS:

  • 10 trials in original meta-analysis
  • Cervical length >25 mm: There was no difference in the frequency of preterm birth <37 weeks between control and progesterone
    • Progesterone: 35.4%
    • Control: 35.4%
    • RR 0.99 (95% CI, 0.84 to 1.16); P=0.88
    • High-quality evidence
  • Cervical length ≤25 mm (‘short cervix’): Vaginal progesterone significantly reduced the risk of preterm birth <37 weeks vs control
    • RR 0.72 (95% CI, 0.58 to 0.90)
    • High-quality evidence
  • Similar results were found for preterm birth <34 weeks and <28 weeks
  • There were no significant differences in the risk of adverse maternal or neonatal outcomes between progesterone and controls

CONCLUSION:

  • There is no evidence that vaginal progesterone prevents preterm birth among women with a singleton gestation, a history of spontaneous preterm birth, and a cervical length >25 mm
  • The authors state

In summary, our findings reaffirm that vaginal progesterone should be offered to patients with a singleton gestation and a history of spontaneous preterm birth only if they have a midtrimester (18-24 weeks of gestation) transvaginal sonographic cervical length ≤25 mm

Learn More – Primary Sources:

Vaginal progesterone does not prevent recurrent preterm birth in women with a singleton gestation, a history of spontaneous preterm birth, and a midtrimester cervical length >25 mm

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

FavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

EPPPIC Meta-analysis Results: Progestogens for Preterm Birth Prevention
RCT Results: Vaginal Progesterone or 17-OHPC for Preventing Recurrent Preterm Birth?
Meta-Analysis: Which Interventions are Best for Preventing Spontaneous Preterm Birth?  
Does Vaginal Progesterone Improve Birth Outcomes for Mothers with Short Cervix?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site